Korean Cancer Association

Curriculum Vitae		
Full name	Daniel Sanghoon Shin	
Current Position	Assistant Professor	
Department	Medicine/Hematology-Oncology	
Affiliation	David Geffen School of Medicine at UCLA	
Country	USA	

Education

Kyung Hee University, Seoul, South Korea, BS, 1998, Preliminary Medicine
Kyung Hee University, Seoul, South Korea, MD, 2002, Medicine
Kyung Hee University hospital, Seoul, South Korea, 2003, Internship, KHU medical center
Jacobi Med Center/AECOM, Bronx, NY, USA, 2007 - 2012, Medicine Residency,
Medical Scientist pathway
UCLA Med Center, LA, CA, USA, 2012-2015, Hematology-Oncology fellowship
David Geffen School of Medicine, LA, CA, USA, 2013 - 2017, PhD, Tumor Immunology

Professional Experience

My career plan is to become an academic physician-scientist dedicated to conducting independent basic/translational cancer research in the field of tumor immunology and immunotherapy.

During my residency, I had 3 years of laboratory research experience as part of the medical scientist pathway training. I worked with Dr. I. David Goldman (director of Einstein Cancer Center) who discovered a new folate transporter (proton-coupled folate transporter; PCFT) to study the structure-function relationship of PCFT from novel loss-of-function mutations causing hereditary folate malabsorption. This experience allowed me to learn the fundamentals of laboratory research and led to 10 publications over 3 years.

I sought a hematology-oncology fellowship after residency and started fellowship training from July 2012 in UCLA. My interest in tumor immunology research aligned with Dr. Antoni Ribas' work and I was able to join his lab from October 2013. Dr. Ribas is one of the main leaders in tumor immunology, especially melanoma targeted and immunotherapy and his research encompasses from bench to bedside.

I completed PhD via UCLA STAR (Specialty Training and Advanced Research) program in June, 2017. I have studied the biology of PD-L1 regulation in melanoma over the past 3 years and was able to identify loss-of-function mutations on *JAK1/2* that associated with primary or acquired resistance to PD-1 blockade. This study aligns with renewed interests in interferon signaling given its critical role in mediating response and resistance to immunotherapy. It will also help us select patients who will not likely respond to PD-1 blockade therapy.

My current research goal is to better understand cancer cell interferon biology in association with immunotherapy and identify suitable agents to be combined with checkpoint blockade immunotherapy to improve therapeutic efficacy.